Dabigatran etexilate--a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity - Wikidata - awgldk - TriplyDB

Dabigatran etexilate--a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity

Dabigatran etexilate--a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity

http://www.wikidata.org/entity/Q28278166

about

Reversal agents for NOACs: Connecting the dots Dabigatran approaching the realm of heparin-induced thrombocytopenia Direct-Acting Oral Anticoagulants: Practical Considerations for Emergency Medicine Physicians Efficacy of prothrombin complex concentrates for the emergency reversal of dabigatran-induced anticoagulation The case for dosing dabigatran: how tailoring dose to patient renal function, weight and age could improve the benefit-risk ratio How to choose appropriate direct oral anticoagulant for patient with nonvalvular atrial fibrillation Apixaban and oral implications Perioperative venous thromboembolic disease and the emerging role of the novel oral anticoagulants: an analysis of the implications for perioperative management Dabigatran-Associated Intracranial Hemorrhage: Literature Review and Institutional Experience Differential benefit risk assessment of DOACs in the treatment of venous thromboembolism: focus on dabigatran Management of the bleeding patient receiving new oral anticoagulants: a role for prothrombin complex concentrates Intracranial hemorrhage Reversal of oral anticoagulation The use of novel oral anticoagulants for thromboprophylaxis after elective major orthopedic surgery New oral anticoagulants in patients with nonvalvular atrial fibrillation: a review of pharmacokinetics, safety, efficacy, quality of life, and cost effectiveness Protocol in managing oral surgical patients taking dabigatran The emergent reversal of coagulopathies encountered in neurosurgery and neurology: a technical note Safety of new oral anticoagulant drugs: a perspective Anticoagulation drug therapy: a review The new oral anticoagulants and the future of haemostasis laboratory testing Care transitions in anticoagulation management for patients with atrial fibrillation: an emphasis on safety No influence of dabigatran anticoagulation on hemorrhagic transformation in an experimental model of ischemic stroke Spotlight on idarucizumab and its potential for the reversal of anticoagulant effects of dabigatran Non-vitamin K antagonist oral anticoagulants and antiphospholipid syndrome Pharmacology of anticoagulants used in the treatment of venous thromboembolism Implications of apixaban for dental treatments New oral anticoagulants: their advantages and disadvantages compared with vitamin K antagonists in the prevention and treatment of patients with thromboembolic events Non-Vitamin K Antagonist Oral Anticoagulant Use in Patients With Atrial Fibrillation and Associated Intracranial Hemorrhage: A Focused Review Recent advances in the development of specific antidotes for target-specific oral anticoagulants Twice- or once-daily dosing of novel oral anticoagulants for stroke prevention: a fixed-effects meta-analysis with predefined heterogeneity quality criteria Anticoagulants and the propagation phase of thrombin generation Reversing the anticoagulation effects of dabigatran.The Reversal of Direct Oral Anticoagulants in Animal Models.Direct thrombin inhibitors.Dabigatran use in a postoperative coronary artery bypass surgery patient with nonvalvular atrial fibrillation and heparin-PF4 antibodies.Hemorrhagic complications associated with dabigatran use.Management of bleeding associated with dabigatran and rivaroxaban: a survey of current practices.The role of prothrombin complex concentrates in reversal of target specific anticoagulants.In vitro and ex vivo Measurement of Prophylactic Dabigatran Concentrations with a New Ecarin-Based Thromboelastometry Test.Increased Thromboembolic Events With Dabigatran Compared With Vitamin K Antagonism in Left Ventricular Assist Device Patients: A Randomized Controlled Pilot Trial

P2860

Q26740248-58E80730-B4DB-4448-9C42-62826742476C Q26744261-1664870A-22BB-427B-B7B0-6A8170F50C28 Q26746917-E30E4B7F-2B36-4D5D-8FD8-31E942DECD06 Q26749141-69A98082-0446-4D18-8974-1A3A43820AD2 Q26776239-7700A2EE-EB36-4D97-9050-B8C4A0CF3DB1 Q26776413-1B61A1E5-A04C-4446-8C51-BB4CAF8F0D34 Q26780328-47724FD1-C667-453B-89AA-62A496FE15A4 Q26781790-462AE367-A587-4BAB-9AF2-CF8CF3FA55A2 Q26783457-7F62E13F-D8F6-4CAE-A135-FF9CA5C856E5 Q26799710-3F2EF495-10A5-4605-8ABF-DD12B703AE76 Q26822974-180AF63D-0C0F-4603-926A-61260B3AEAD8 Q26825331-78B78C50-C565-4BEA-938C-E73901696EC9 Q26827835-54B336A1-261B-4A93-8E86-0FB306D23BCF Q26828439-F1462504-3537-4D8F-B5BA-700378FDFD58 Q26863548-53BF14DF-81F3-4C81-843B-0E2DA1FC2968 Q27006890-69DFD441-9F8C-44DF-B311-9AB7589DA92E Q27014959-4CFF7310-D9A9-4490-B2A1-6BF58D64F2D2 Q27016072-6DBF8898-34B1-4B1D-914B-24FAF7897BD0 Q27021871-18C84C19-AD4C-40FF-BAEB-8D338D03C6AF Q27022461-19CE7090-6145-457A-87D6-ABCEB06C8EF5 Q27025527-C0F0CD52-825C-43D0-891A-CA508137C077 Q27334041-BD92EB2E-143C-410F-BE5A-BB488B45741D Q28066262-1D15A6B9-4BFB-4CF5-A5F8-201CF3F7BE89 Q28067420-B5C96DA3-F386-44CC-B900-D4CAD668483B Q28078967-D9413AF4-2343-4F82-AFF6-227020C810BD Q28079697-A2E91578-4627-4D1F-B370-4D0DD4F0885C Q28080616-2D6BEA21-E931-4806-A27C-9C0244AA83CF Q28081918-DF17F6A3-D888-43C5-B252-E626E5C1153B Q28256340-96DD11C7-E64A-42EA-A0D9-24833FC6CA05 Q28539517-5C453658-3584-4D87-A6AD-C800BF02BBFA Q28742536-50CD476E-3414-44EB-9206-62BAA85B7595 Q30400249-CCC3475E-7E3E-47C7-AA9D-79FAA33C8BC0 Q30491580-57BF9A4F-432B-4C19-AC43-4E887C01FB23 Q33393692-BB5CB39F-52EA-49C6-8F2E-7536285C5BE5 Q33398934-FCCBB18E-30F4-4DAD-B2B7-6644B4CAF90E Q33403265-2745C0FB-040A-4951-BEF5-78FC59203DA8 Q33556350-A0FF5871-8B45-4296-8CEE-85A6C869AB3D Q33582537-8873ED7D-4B80-4CD7-B7D5-CBDE11550672 Q33659485-5ABE9073-75FE-48AB-B258-B60B76AADF60 Q33698353-4A46D7C9-DF37-4B72-82F1-9362823AB630

P2860

Dabigatran etexilate--a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity

http://www.wikidata.org/entity/Q28278166

description

2010 nî lūn-bûn

@nan

2010 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Dabigatran etexilate--a novel, ...... rsal of anticoagulant activity

@ast

Dabigatran etexilate--a novel, ...... rsal of anticoagulant activity

@en

Dabigatran etexilate--a novel, ...... rsal of anticoagulant activity

@nl

type

label

Dabigatran etexilate--a novel, ...... rsal of anticoagulant activity

@ast

Dabigatran etexilate--a novel, ...... rsal of anticoagulant activity

@en

Dabigatran etexilate--a novel, ...... rsal of anticoagulant activity

@nl

prefLabel

Dabigatran etexilate--a novel, ...... rsal of anticoagulant activity

@ast

Dabigatran etexilate--a novel, ...... rsal of anticoagulant activity

@en

Dabigatran etexilate--a novel, ...... rsal of anticoagulant activity

@nl

P1433

Q28278166-5DAA7879-AE1C-48F3-BB96-AD16912DC360

P1476

Q28278166-1D091A2E-5472-48B5-9C05-080FD1B13A69

P2093

Q28278166-2CE3BDBD-A259-47C9-9CB7-BD6BF5ABEC57

Q28278166-38255C0D-7A01-4EED-91B9-AEB3D20E53FB

Q28278166-5C47CAC0-BD60-49A2-B539-42BC3BACB4AD

Q28278166-788D02C8-97D1-486E-BFFA-24DA27282A5F

Q28278166-A10336AE-B5C5-465A-B6F7-3CDCFD32C563

Q28278166-DB1FCB83-6184-4857-8BD8-3EECA5F1D799

Q28278166-E5C786DD-8CC5-4AB4-9EEF-9B20BACA467E

P304

Q28278166-65237D05-0209-42BD-8C08-BD690A7A9EED

P31

Q28278166-4A7EFE56-8957-419F-A6C2-A7BB9618567F

P3181

Q28278166-F3B8C60F-387F-4ABC-A025-A19526B6B9DD

P356

Q28278166-13AFE5CF-075C-405C-A748-088AA973B70D

P407

Q28278166-EB1C6E9B-0C78-44CE-820F-5E0D9C1A4DB1

P433

Q28278166-E03293D5-478A-483D-BE92-18265C4A6EAE

P478

Q28278166-BAC0E63A-BAA3-4E3B-AF94-8D2030ECAD7A

P577

Q28278166-9BC21C8A-2879-4C71-A724-521EDC8111DF

P698

Q28278166-E80AD5B6-314B-45BD-81DC-46D28243A7D5

P921

Q28278166-DAE8518A-7932-42E0-9454-FCFC15E325C5

P3181

P356

P1433

Thrombosis and Haemostasis

P1476

Dabigatran etexilate--a novel, ...... rsal of anticoagulant activity

@en

P2093

Andreas Clemens

http://www.w3.org/2001/XMLSchema#string

Joachim Stangier

http://www.w3.org/2001/XMLSchema#string

Joanne van Ryn

http://www.w3.org/2001/XMLSchema#string

Karl-Heinz Liesenfeld

http://www.w3.org/2001/XMLSchema#string

Martin Feuring

http://www.w3.org/2001/XMLSchema#string

Sebastian Haertter

http://www.w3.org/2001/XMLSchema#string

Wolfgang Wienen

http://www.w3.org/2001/XMLSchema#string

P304

1116-27

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

249649

http://www.w3.org/2001/XMLSchema#string

P356

10.1160/TH09-11-0758

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

103

http://www.w3.org/2001/XMLSchema#string

P577

2010-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

20352166

http://www.w3.org/2001/XMLSchema#string

P921

anticoagulation